Minneapolis, MN6 Active Studies

Multiple Myeloma Clinical Trials in Minneapolis, MN

Find 6 actively recruiting multiple myeloma clinical trials in Minneapolis, MN. Connect with local research sites and explore new treatment options.

6
Active Trials
5
Sponsors
1,693
Enrolling

Recruiting Multiple Myeloma Studies in Minneapolis

About Multiple Myeloma Clinical Trials in Minneapolis

Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.

There are currently 6 multiple myeloma clinical trials recruiting participants in Minneapolis, MN. These studies are seeking a combined 1,693 participants. Research is being sponsored by AbbVie, Center for International Blood and Marrow Transplant Research, National Cancer Institute (NCI) and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Multiple Myeloma Clinical Trials in Minneapolis — FAQ

Are there multiple myeloma clinical trials in Minneapolis?

Yes, there are 6 multiple myeloma clinical trials currently recruiting in Minneapolis, MN. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Minneapolis?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Minneapolis research site will contact you about next steps.

Are clinical trials in Minneapolis free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Minneapolis studies also compensate for your time and travel.

What multiple myeloma treatments are being tested?

The 6 active trials in Minneapolis are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.

Data updated July 17, 2026 from ClinicalTrials.gov